Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 16, Number 8—August 2010
CME ACTIVITY - Synopsis

Clostridium difficile Bacteremia, Taiwan1

Nan-Yao Lee, Yu-Tsung Huang, Po-Ren Hsueh2, and Wen-Chien Ko2Comments to Author 
Author affiliations: National Cheng Kung University Hospital and Medical College, Tainan, Taiwan (N.-Y. Lee, W.-C. Ko); National Taiwan University Hospital and College of Medicine, Taipei, Taiwan (Y.-T. Huang, P.-R. Hsueh); 1This study was presented in part at the Annual Meeting of the Infectious Disease Society of Taiwan, Taipei, Taiwan, January 9–10, 2010.; 2These authors contributed equally to this article.

Main Article

Table 2

Summary of clinical characteristics of 12 patients with Clostridium difficile bacteremia in the current series from Taiwan, 1989–2009, and of 20 additional cases published since 1962*

Characteristic Total, n = 32 Reported cases, n = 20 Current series, n = 12 p value
Age, y, mean ± SD 51.4 ± 26.1 46.2 ± 27.5 59.9 ± 22.2 0.14
Elderly, age >60 y 18 (56.3) 11 (55.0) 7 (58.3) 1.0
Male
19 (59.4)
14 (70.0)
5 (41.7)
0.15
Place of acquisition 0.70
Community 12/28 (42.9) 5/16 (73.3) 7 (58.3)
Hospital
16/28 (57.1)
11/16 (26.7)
5 (41.7)

Calendar year range 0.001
1962–1990 8 (25) 8 (40.0) 0
1991–2000 8 (25) 7 (35.0) 1 (8.3)
After 2000
16 (50)
5 (25.0)
11 (91.7)

Comorbidity
Malignancy 9 (28.1) 6 (30.0) 3 (25.0) 1.0
Congestive heart failure 4 (12.5) 3 (15.0) 1 (8.3) 1.0
Immunosuppression 7 (21.9) 2 (10.0) 5 (41.7) 0.07
Chronic obstructive pulmonary disease 3 (9.4) 2 (10.0) 1 (8.3) 1.0
Chronic kidney disease 3 (9.4) 1 (5.0) 2 (16.7) 0.54
Liver cirrhosis 7 (21.9) 1 (5.0) 6 (50.0) 0.006
Cerebrovascular accident 2 (6.3) 1 (5.0) 1 (8.3) 1.0
Diabetes mellitus 4 (12.5) 0 4 (33.3) 0.014
Organ transplant 2 (6.3) 0 2 (16.6) 0.13
None
6 (18.8)
6 (30.0)
0
0.06
Clinical signs and symptoms
Fever 19/27 (70.4) 10/15 (66.7) 9 (75.0) 0.70
Abdominal pain 14/29 (48.3) 8/17 (47.1) 6 (50.0) 1.0
Diarrhea
12/28 (42.9)
8/16 (50.0)
4 (33.3)
0.46
Gastrointestinal disease or condition 10/28 (35.7) 5/16 (31.3) 5 (41.7) 0.7
Gastrointestinal bleeding 5/27 (18.5) 0/15 (0.0) 5 (41.7) 0.01
Gastrointestinal perforation 3/28 (10.7) 2/16 (12.5) 1 (8.3) 1.0
Pseudomembranous colitis
5/27 (18.5)
3/15 (20.0)
2 (16.7)
1.0
Recent antimicrobial drug exposure
18/26 (69.2)
13/14 (92.9)
5 (41.7)
0.009
Sources of bacteremia
Primary 17 (53.1) 10 (50.0) 7 (58.3) 0.73
Intraabdominal infection 11 (34.4) 7 (35.0) 4 (33.3) 1.0
Urosepsis 2 (6.3) 2 (10.0) 0 0.52
Skin and soft tissue infection 2 (6.3) 1 (5.0) 1 (8.3) 1.0
Bone and joint infection 1 (3.1) 0 1 (8.3) 0.38
Polymicrobial bacteremia
20 (62.5)
14 (70.0)
6 (50.0)
0.29
Positive clostridial toxin assay result 14/22 (63.6) 9/12 (75.0) 5/10 (50.0) 0.42
Crude death rate 15/31 (48.4) 10/19 (52.6) 5 (41.7) 0.72

*Values are no. patients (%) or no. patients/total no. patients evaluated (%), except for age. Patients may have >1 morbidity, clinical sign or symptom, and gastrointestinal disease or condition.

Main Article

Page created: March 30, 2011
Page updated: March 30, 2011
Page reviewed: March 30, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external